Latest News

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Beyond the Injection: The Future of Holistic GLP-1 Care

Beyond the Injection: The Future of Holistic GLP-1 Care

The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....

read more
Biotech IPO Surge: 2026’s First Half Beats 2025

Biotech IPO Surge: 2026’s First Half Beats 2025

Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...

read more
Why AI May Increase Cognitive Burden Before Reducing It

Why AI May Increase Cognitive Burden Before Reducing It

It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...

read more
Weekly News Roundup | 15 June 2026

Weekly News Roundup | 15 June 2026

Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...

read more
Beyond the Injection: The Future of Holistic GLP-1 Care

Beyond the Injection: The Future of Holistic GLP-1 Care

The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....

read more
Biotech IPO Surge: 2026’s First Half Beats 2025

Biotech IPO Surge: 2026’s First Half Beats 2025

Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...

read more
Why AI May Increase Cognitive Burden Before Reducing It

Why AI May Increase Cognitive Burden Before Reducing It

It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...

read more
Weekly News Roundup | 15 June 2026

Weekly News Roundup | 15 June 2026

Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Why Europe’s Precision Oncology Trials Keep Stalling

Why Europe’s Precision Oncology Trials Keep Stalling

Precision medicine works when the right biomarker test reaches the right patient in time. In Europe, the regulatory plumbing is making that harder than it should be. At the 16th Clinical Biomarkers & CDx Summit in London in March 2026, I discussed lessons from MDx...

read more
Complement Inhibitor Setback: Sanofi Halts CIDP Study

Complement Inhibitor Setback: Sanofi Halts CIDP Study

Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...

read more
Clinical Trials Roundup | 12 June 2026

Clinical Trials Roundup | 12 June 2026

Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...

read more
Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026

Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026

The oral GLP-1 market has changed faster in the past six months than in the previous six years. Where once Rybelsus stood alone as the only GLP-1 pill available, patients and clinicians must now navigate three distinct oral products, each with a different molecule, a...

read more
FDA Drug Approval Decisions: June and July 2026

FDA Drug Approval Decisions: June and July 2026

The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...

read more
Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...

read more
Dementia Relief Through Silence and Brain Wave Modulation

Dementia Relief Through Silence and Brain Wave Modulation

In silence, the brain regenerates, growing new neurons in the hippocampus which is the cerebral center of memory, spatial navigation and emotional regulation (Kriste, Nicola, Kronenberg, Walker, Liu, & Kempermann, 2015). Silence has also been shown to be relaxing...

read more

Further News

Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery

The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...

Weekly News Roundup | 07 September 2026

Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...

Alexander Disease Treatment Approved: What It Means for UK Access

The United States Food and Drug Administration has approved the first Alexander disease treatment. Zanvastro (zilganersen) was cleared on 3 September 2026 for paediatric and adult patients. Ionis Pharmaceuticals developed the antisense oligonucleotide. The decision...

Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven

Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...

Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed

Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...

New Biology, New Opportunities in Women’s Health

Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...

Clinical Trials Roundup | 4 Sept 2026

Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...

The Scale-Up Test

A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...

ACTO Achieves Veeva Gold Product Partner Status

Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...

Huntington Gene Therapy Submission Reaches FDA and MHRA

uniQure filed the Huntington gene therapy submission with the FDA and MHRA on 2 September 2026. Inside the three-year data and the regulatory reset.

    GLP-1 Indications: The 2026 Regulatory Status Map

    The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...

    AI in MedTech: Accelerating the Product Development Lifecycle

    Developing a new medical device is a lengthy, complex process that typically takes between three to seven years from conception to market [1]. For MedTech companies operating within highly regulated environments where compliance and patient safety are paramount,...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.